The upward curve of technological progress is steepening, and this is particularly the case for the development of medical biotechnologies capable of meaningfully addressing the causes of aging. These are the acceleration years, in which the first rejuvenation therapies exist in prototype form, commercial development begins in earnest, and funding starts to pour into the field. That in turn drives funding into many neighboring areas of fundamental research that have previously struggled, bringing further rejuvenation therapies closer to viability. If you look at the outset of past fields of human scientific endeavor, most are stories of decades, sometimes generations, of painfully slow, unsupported attempts to make progress. Then all of of a sudden, in the course of a decade, the tipping point is reached and an entire industry blossoms into being. We are just about there for rejuvenation biotechnology; it is the end of the lengthy beginning, and the start of a great and energetic new phase of development.
It is customary, in techno-visionary circles, to base one’s expectations of the future on the principle of exponentially accelerating change. The often uncannily accurate timeframe predictions of Ray Kurzweil have engendered